



General Meeting of Kuros Biosciences approves all resolutions

May 23, 2017

Kuros Biosciences announced that yesterday's General Meeting approved all resolutions proposed by the Board of Directors with a vast majority. In particular, shareholders resolved on an increase of the conditional and authorized capital. Prof. Dr. Clemens van Blitterswijk, Frank-Jan van der Velden, Giacomo Di Nepi and Dr. Ivan Cohen-Tanugi were elected as new members of the Board of Directors. A total of 36.1 % of shares were represented at the General Meeting.

Schlieren (Zurich), Switzerland, May 23, 2017

The General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2016 and took note of the Reports of the Auditors. Shareholders also voted in favor of the proposed appropriation of the Annual Results, discharged the members of the Board and the Executive Committee and approved their compensation.

Dr. Christian Itin was re-elected as Chairman as were Leanna Caron, Didier Cowling, Dr. Gerhard Ries and Harry Welten as members of the Board. Shareholders also elected Prof. Dr. Clemens van Blitterswijk, Frank-Jan van der Velden, Giacomo Di Nepi and Dr. Ivan Cohen-Tanugi as new Board members. Dr. Ries and Leanna Caron were elected as members of the Compensation Committee. Finally, the current Independent Proxy as well as the Auditors were confirmed for another term.

Dr. Christian Itin, Chairman of the Board, commented on the election of Prof. Dr. van Blitterswijk, Dr. Cohen-Tanugi and Messrs van der Velden and Di Nepi: „Kuros is in transition to become a commercial-stage orthobiologics company. Ahead of the market launches of our product lines MagnetOs™ and Neuroseal, we strengthen the commercial and scientific expertise on the Board level.” He continued: „We thank Dr. Arnd Kaltoven and Dr. Jörg Neermann who did not stand for re-election. As long-time Board members, Arnd and Jörg sustainably contributed to Kuros' development.“

Shareholders also resolved on an increase of the authorized (to 3,224,661 registered shares) and conditional share capital for Employee Benefits (to 1,208,389 registered shares) and corresponding changes to the Articles of Incorporation.

The General Meeting took place at the Company's headquarters in Schlieren. It was attended by 36 shareholders. 2,326,113 shares or 36.1% of a total of 6,449,323 shares were represented.

Updated company presentation

An updated corporate presentation is available under the following link: www.kuros.ch/investors/reports-presentations.html.

About Kuros Biosciences Ltd

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kuros.ch for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results

expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

Kuros Biosciences Ltd

Harry Welten, MBA

Chief Financial Officer

Tel: +41 79 750 15 64

harry.welten@kuros.ch